SCHOTT Pharma (1SXP) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenues rose to EUR 252 million, up 10% at constant currencies, driven by strong demand for high-value solutions (HVS) in both drug containment and delivery segments.

• EBITDA surged 63% year-on-year to EUR 72 million, with a margin of 28.6% (28.2% at constant currencies), reflecting a favorable product mix and efficiency measures.

• HVS sales accounted for 56% of total revenues, reinforcing the strategic shift toward higher-margin offerings.

• Innovation and expansion, including new patented products and production facilities, supported growth and market positioning.

Financial highlights

• Q2 2025 revenue: EUR 252 million (+10% at constant currencies).

• EBITDA: EUR 72 million (+63% year-on-year), margin 28.6% (28.2% at constant currencies).

• Earnings per share increased 54% to EUR 0.26.

• Free cash flow for Q2 was EUR 19 million; H1 2025 free cash flow at EUR 22 million.

• Capital expenditures in Q2 totaled EUR 30 million, focused on expansion in Serbia and Hungary.

Outlook and guidance

• Full-year 2025 targets confirmed: high single-digit organic revenue growth and EBITDA margin around prior year’s 26.9%.

• HVS revenue share expected to remain strong at approximately 55%, with a mid-term target of over 60%.

• CapEx guidance for FY2025 is EUR 140-160 million, with a EUR 20 million reduction due to market volatility.

• Q3 2025 revenue expected to grow mid-single-digit % over Q2, with stable EBITDA margin.